Badía X, Gil A, Poveda-Andrés JL, Shepherd J, Tort M. Análisis de los criterios sobre precio y financiación de los medicamentos huérfanos en España. Farm Hosp. 2019; 43(4):121-127.

Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, et al. Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discov Today. 2018; 23(2): 424-433.

Detiček A, Locatelli I, Kos M. Patient Access to Medicines for Rare Diseases in European Countries. Value Health. 2018; 21(5): 553-560.

Héon-Klin V. European Reference Networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017; 12: 137. Published online 2017 [DOI: 10.1186/s13023-017-0676-3].

Comentado por:

Marta Trapero-Bertran
Profesora titular e Investigadora de la Universitat Internacional de Catalunya (UIC)

Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, et al. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. J Market Access Health Policy. 2016; 4: 33039 [DOI: 10.3402/jmahp.v4.33039]

Comentado por:

Marta Trapero-Bertran
Profesora titular e Investigadora de la Universitat Internacional de Catalunya (UIC)